JD HEALTH
06618
NTES-S
09999
JD-SW
09618
4
TENCENT
00700
5
BABA-W
09988
(FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -1.33%6.06B | 5.87%3.07B | 2.70%6.14B | 1.87%2.9B | 15.03%5.98B | -3.42%2.85B | -6.13%5.2B | -0.36%2.95B | -12.87%5.54B | -5.40%2.96B |
Operating income | -1.33%6.06B | 5.87%3.07B | 2.70%6.14B | 1.87%2.9B | 15.03%5.98B | -3.42%2.85B | -6.13%5.2B | -0.36%2.95B | -12.87%5.54B | -5.40%2.96B |
Cost of sales | -4.04%-2.02B | -3.67%-996.03M | -5.31%-1.94B | -19.98%-960.75M | -2.09%-1.84B | 19.76%-800.74M | -16.43%-1.8B | -30.57%-997.98M | -4.76%-1.55B | -9.35%-764.34M |
Operating expenses | -4.04%-2.02B | -3.67%-996.03M | -5.31%-1.94B | -19.98%-960.75M | -2.09%-1.84B | 19.76%-800.74M | -16.43%-1.8B | -30.57%-997.98M | -4.76%-1.55B | -9.35%-764.34M |
Gross profit | -3.80%4.04B | 6.96%2.08B | 1.54%4.2B | -5.21%1.94B | 21.90%4.14B | 4.93%2.05B | -14.88%3.4B | -11.11%1.95B | -18.21%3.99B | -9.63%2.2B |
Selling expenses | 11.66%-1.82B | 23.71%-850.83M | -13.00%-2.06B | -33.06%-1.12B | -6.74%-1.82B | -8.75%-838.15M | -2.46%-1.7B | 11.80%-770.73M | 18.23%-1.66B | 13.37%-873.86M |
Administrative expenses | 9.63%-581.96M | 2.75%-289.18M | -10.48%-643.97M | -11.71%-297.34M | -2.11%-582.87M | 5.57%-266.18M | -9.47%-570.84M | -13.65%-281.87M | 1.47%-521.48M | 4.12%-248.02M |
Operating interest expense | ---- | ---- | ---- | ---- | ---- | -9.25%-214.11M | 5.79%-399.46M | ---195.98M | -43.50%-424M | ---- |
Special items of operating profit | -88.78%-244.06M | -2,820.00%-131.08M | 78.35%-129.28M | 101.35%4.82M | 25.05%-597.27M | -64.42%-356.83M | -80.79%-796.92M | -28.07%-217.02M | -13.93%-440.79M | 6.39%-169.45M |
Operating profit | 1.97%1.4B | 50.76%807.47M | 20.52%1.37B | 42.90%535.59M | 1,615.70%1.14B | -23.21%374.81M | -108.00%-75.26M | -46.16%488.08M | -42.40%940.45M | -7.85%906.53M |
Financing cost | 16.83%-561.79M | 9.45%-277.84M | -43.18%-675.45M | ---306.84M | ---471.76M | ---- | ---- | ---- | ---- | -84.84%-222.98M |
Share of profits of associates | -197.48%-774K | 48.71%345K | -4.45%794K | -59.15%232K | 18.54%831K | 58.66%568K | -59.39%701K | -65.11%358K | 42.17%1.73M | 211.85%1.03M |
Earning before tax | 19.87%839.22M | 131.44%529.98M | 4.53%700.1M | -39.00%228.99M | 998.32%669.76M | -23.15%375.37M | -107.91%-74.56M | -28.65%488.44M | -42.34%942.17M | -20.71%684.58M |
Tax | -20.61%-194.21M | -9.76%-91.8M | -86.23%-161.02M | -15.86%-83.63M | -23.13%-86.47M | 10.27%-72.19M | 70.61%-70.23M | 44.23%-80.45M | 14.62%-238.91M | 14.17%-144.25M |
After-tax profit from continuing operations | 19.65%645.01M | 201.46%438.18M | -7.58%539.08M | -52.06%145.35M | 502.88%583.3M | -25.69%303.19M | -120.59%-144.78M | -24.49%407.99M | -48.06%703.27M | -22.29%540.33M |
Earning after tax | 19.65%645.01M | 201.46%438.18M | -7.58%539.08M | -52.06%145.35M | 502.88%583.3M | -25.69%303.19M | -120.59%-144.78M | -24.49%407.99M | -48.06%703.27M | -22.29%540.33M |
Minority profit | 2,574.94%173.12M | 1,188.95%50.34M | 130.09%6.47M | -174.70%-4.62M | -107.02%-21.51M | -71.09%6.19M | -212.89%-10.39M | 2,247.04%21.41M | 92.11%-3.32M | 102.54%912K |
Profit attributable to shareholders | -11.40%471.89M | 158.60%387.84M | -11.94%532.61M | -49.50%149.98M | 550.03%604.81M | -23.17%297M | -119.02%-134.39M | -28.33%386.59M | -49.39%706.59M | -26.23%539.42M |
Basic earnings per share | -12.25%0.1254 | 153.94%0.1031 | -17.78%0.1429 | -52.46%0.0406 | 545.64%0.1738 | -24.56%0.0854 | -117.59%-0.039 | -33.02%0.1132 | -49.13%0.2217 | -25.97%0.169 |
Diluted earnings per share | -12.25%0.1254 | 153.94%0.1031 | -17.78%0.1429 | -52.46%0.0406 | 545.64%0.1738 | -24.36%0.0854 | -117.63%-0.039 | -33.04%0.1129 | -48.96%0.2212 | -25.79%0.1686 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- |
Auditor | -- | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.